Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Lupin updates on shipment of Mirabegron ER Tablets
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The product is used to treat amyotrophic lateral sclerosis
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subscribe To Our Newsletter & Stay Updated
